

Special Issue

Clinical Advances and State-of-the-Art Management in Genitourinary Cancers

Message from the Guest Editors

Genitourinary (GU) malignancies represent a variety of tumors within the urinary and male reproductive systems, requiring individualized treatment plans to meet the distinct needs of each patient. Although most GU malignancies are well managed in the early stages, the advanced stages of many such cancers have a poor prognosis. Limited treatment options and poor prognosis represent an unmet need in advanced GU malignancies. The development of novel therapies for advanced GU cancers relies on comprehension of underlying biological mechanisms, and several research efforts have focused on genomic profiling, diagnostic biomarkers, tumor immune microenvironment (TIME), and molecular pathways of oncogenesis. The focus of this Special Issue is to consider research efforts pertaining to: (a) tumor biology, genomic characterization, and microenvironment; and (b) exploration of novel therapies in genitourinary malignancies.

Assistant

Guest Editors

Dr. Jad Chahoud

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

Dr. Adnan Fazili

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

Deadline for manuscript submissions

closed (25 May 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/215629

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)